Intermune to raise some $60 million in stock offering(0)
Have good news, will sell stock. That might be the logic behind a secondary offering of new shares by InterMune, the Brisbane biotechnology company whose stock price soared 28 percent to earlier this month after it said it would apply for approval in the Read the rest of this entry »
Subscribe via RSS all feeds